Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JJ.

J&J orthopedics unit draws Apollo interest in potential $20 billion deal: Report

Apollo Global Management is in discussions to acquire Johnson & Johnson's orthopedics division, which could be worth around twenty billion dollars. In addition to this, Johnson & Johnson is contemplating the option of spinning off this unit into a separate public entity. This strategy aligns with the company's aim to…

The Economic Times

Wells drying up at South Dakota homes and ranches due to heat and drought

Gordon and Connie Howie are struggling with water shortages on their cattle ranch in western South Dakota

The Independent UK

Johnson & Johnson seeks to end decade-long talc litigation with $5.5 billion settlement

Johnson & Johnson has struck a substantial deal worth more than five billion dollars, aimed at settling numerous lawsuits that allege cancer linked to its talc products. Following an ineffective bankruptcy resolution attempt, this latest agreement will facilitate quicker claims disbursement while keeping the door open for others who develop…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

J&J reaches sweeping talc product settlement

NEW YORK - ‌Johnson & Johnson has announced that it will pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc products cause ovarian cancer, in a landmark deal that could end a contentious legal battle that has dogged the company…

Bangkok Post

Johnson & Johnson reaches $5.5 bn talc settlement that could end decade of litigation

Johnson & Johnson will pay an estimated $5.5 billion to resolve talc product lawsuits. This landmark deal covers approximately seventy-six thousand claims alleging cancer causation. The company previously settled most claims involving asbestos and mesothelioma litigation. Johnson & Johnson expects to pay $3 billion in 2027 and further payments in…

The Economic Times

J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock.

J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.

Barchart

Johnson & Johnson beats lawsuit alleging that talc caused three women's cancer

A Los Angeles jury ruled in favor of Johnson & Johnson, finding the company not negligent in a lawsuit alleging its talc products caused ovarian cancer. This verdict comes as J&J faces thousands of similar claims, having previously won some cases and lost others, and having discontinued talc-based baby powder…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

3 Dividend Kings That Earn Their Crown Every Quarter

These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

MarketBeat

Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study

The study, which followed patients for over five ‌years, found that those ⁠who received ⁠the regimen were nine times more likely to have little to no detectable cancer in the prostate at the time of surgery compared with those given testosterone-blocking therapy alone.

The Economic Times

3 Dividend Kings to Buy Now to Replace the Social Security Income You're About to Lose

The Congressional Budget Office (CBO) released a report this year containing one number that should change how every American near retirement thinks about income. Here's 3 dividend stocks to replace that lost income.

Barchart

Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential

Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist. Sp

MarketBeat

Is This Dividend King With a 63-Year Dividend Streak A Buy Before April 14?

This Dividend King offers a rare mix of safety and upside heading into earnings.

Barchart

This bathroom took a risk mixing patterned tiles and wallpaper, and the finished result is beautiful

This homeowner trusted her instincts when choosing colours and wallpapers, resulting in an eye-catching bathroom

Ideal Home

2 Safe Dividend Stocks to Buy and Hold Forever

These are two dividend stocks that you can confidently buy, hold, and forget about for decades.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

Johnson & Johnson provides stability through decades of dividend growth while pivoting to high-margin medical technology to outperform the volatile market.

Saving Advice

5 Dividend Stocks Retirees Are Favoring for Steady Income in 2026

Retirees in 2026 are looking for something simple: predictable income without unnecessary risk. With inflation still pressuring household budgets and bond yields bouncing around, many...

Barchart

1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

Ideal Home

I have this thing for pretty picture frames – these are my 8 go-to places to shop for the best ones, whether you're framing photos or art prints

Where to buy frames to elevate your walls and the rest of your home with

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

The Independent UK

Johnson & Johnson ordered to pay women over talcum powder cancer cases

The healthcare giant immediately announced its intention to appeal the liability verdict and compensatory damages

Fortune

Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers

Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.

Guitar World

“Took us totally by surprise – sirloin steak quality for chicken nuggets price”: Jet Guitars JT-350 BKM H and JJ-300 P90 SFG review

These guitars have outlines that you'll recognise, but their meagre price points surely belie the set of specs and level of build quality? Let’s find out

Evening Standard

Johnson & Johnson lawsuit explained: Families sue over baby powder cancer claims

Thousands in the UK are suing Johnson & Johnson, alleging that the company's baby powder products concealed cancer risks

International Business Times UK

64-Year-Old Blames Johnson & Johnson for Her Ovarian Cancer — Joins 3,000 Suing the Pharma Giant

UK's first talc cancer group claim accuses Johnson & Johnson and Kenvue of failing to warn about asbestos risk — £1 billion suit backed by 3,000 claimants.

The Guardian - UK

Thousands in UK take legal action against Johnson & Johnson over alleged talc cancer link

High court claim says company knowingly sold product containing asbestos and ‘concealed’ risk to public

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.